Boston Scientific Corporation $BSX Stock Holdings Lessened by Atle Fund Management AB

Atle Fund Management AB lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 31.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 86,680 shares of the medical equipment provider’s stock after selling 39,505 shares during the period. Boston Scientific accounts for approximately 3.3% of Atle Fund Management AB’s holdings, making the stock its 11th biggest position. Atle Fund Management AB’s holdings in Boston Scientific were worth $8,463,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. State Street Corp lifted its holdings in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the last quarter. Synergy Asset Management LLC raised its holdings in shares of Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock worth $48,297,000 after purchasing an additional 479,593 shares in the last quarter. Gladstone Institutional Advisory LLC lifted its stake in Boston Scientific by 39.5% during the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after purchasing an additional 14,700 shares during the last quarter. Channel Wealth LLC boosted its holdings in Boston Scientific by 70.8% during the third quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock worth $2,790,000 after buying an additional 11,847 shares in the last quarter. Finally, Bank of Nova Scotia grew its position in Boston Scientific by 106.4% in the second quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock worth $324,971,000 after buying an additional 1,559,605 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $93.58 on Friday. The business’s 50-day moving average is $95.21 and its 200-day moving average is $99.49. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The company has a market capitalization of $138.72 billion, a price-to-earnings ratio of 50.04, a P/E/G ratio of 1.64 and a beta of 0.67. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on BSX shares. The Goldman Sachs Group reiterated a “buy” rating and set a $112.00 price objective on shares of Boston Scientific in a research report on Friday, January 9th. Evercore ISI set a $112.00 target price on Boston Scientific in a report on Monday, January 5th. Oppenheimer dropped their price target on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Morgan Stanley upped their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $123.89.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 80,204 shares of company stock worth $7,998,563 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.